Pricing Log in Create free account
Friday 6 November 2026 Export CBIO’s income statement to Excel — free account

Crescent Biopharma, Inc.

CBIO Healthcare Biotechnology

Crescent Biopharma, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $10.8 million, up 108,340.0% from fiscal 2023.

Revenue
+1,038,900.0%
EPS
+85.0%
Free cash flow
−7.04%

Quarter to June 2026, against a year earlier

13.48 0.54 +4.17%
Market cap
$480.6M
P/E
0.0×
Fwd P/E
−4.6×
Dividend yield
—
F-score
n/a
Altman Z
−0.06
Beneish M
n/a
Dividend safety
n/a
Overview
Financials
Income Statement Balance Sheet Cash Flow Metrics & Ratios

Insider Decisions last twelve months

Bought, $m 30.61
Sold, $m 1.51
Trades a month
Jan 26 Apr 26 Jul 26 Oct 26
Buy 1 — — — — — — 1 — — — —
Sell — — — — — — 7 — — 7 — —
Insider Ownership 0.00%

Capital & Financial Ratios $m

Size
Market Cap 480.64
Revenue ttm 1.22
Net income ttm (165.12)
Free cash flow ttm (71.85)
Net debt Q (171.59)
Valuation
P/E 0.00
Forward P/E (4.60) (negative: loss-making)
Price / sales 337.85 (above 10: high)
Forward P/S Powerpack
Price / FCF 0.00
Price / book 2.58
Financial health
Current ratio Q 9.66 (at or above 1.5: strong)
Debt / equity Q 0.00 (at or below 0.5: strong)
Interest coverage Q (82.28)
Growth
Revenue growth Q +1,038,900.00% (above 0%: growing)
Operating income growth Q −25.36% (below 0%: shrinking)
EPS, this year +78.41% (at or above 15%: strong)
EPS, next year A −5.24% (below 0%: weak)
Revenue, next year A −84.09% (below 0%: weak)
EPS, past 5 yrs —
EPS, next 5 yrs A +37.95% (at or above 15%: strong)

Green and red mark values outside typical ranges; (Q) is the latest quarter, (A) analysts’ estimates. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 228×, against a ten-year median of 5.1×; over the ten years it ranged from −423× in 2026 to 854× in 2025.
P/S against its own 10 years 76.69%
10-year low 10-year high
P/B against its own 10 years 61.36%
10-year low 10-year high
EV/Sales against its own 10 years 73.58%
10-year low 10-year high

Dividends

Yield
—
Annual rate
—
Payout ratio
—

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 42 35 213 172
Receivables — — 18 —
Inventory — — — —
Other — — — —
44 35 237 179
2023 2024 2025 Q'26
Payables 1 7 10 3
ST’ Debt — — — —
Other — 0 5 5
7 10 36 19

Compound Annual Growth %

10y 5y 3y
Sales — 257.77% 110.67%
Cash Flow 0.00% 0.00% 0.00%
Earnings 0.00% 0.00% 0.00%
Book Value 17.50% 9.63% 67.85%

Earnings Trends EPS, adjusted, against the consensus

Q2 FY26 Estimate −0.70 Actual −0.74

Earnings per share against the consensus, by quarter
Quarter Estimate Reported Result
Q3 FY25 −1.01 −1.27 Miss by 0.26
Q4 FY25 −2.22 −4.01 Miss by 1.79
Q1 FY26 −0.85 −0.70 Beat by 0.15
Q2 FY26 −0.70 −0.74 Miss by 0.04
Q3 FY26 −0.57 — Reports 5 November 2026

EPS $

Mar Jun Sep Dec Year
’26 (0.70) (0.74) — — —
’25 (19.62) (4.93) (1.27) (4.01) (12.81)
’24 (17.00) (16.00) (15.00) (11.20) (58.75)
’23 (17.00) (13.00) (14.00) (14.00) (58.00)
’22 (28.00) (25.00) (16.00) (19.00) (89.00)
’21 (28.00) (28.00) (34.00) (33.00) (123.00)
’20 (18.00) (32.00) (29.00) (32.00) (112.00)
Fiscal quarters ending in the months shown.

Revenue $m

Mar Jun Sep Dec Year
’26 1 — — — —
’25 — — — — 11
’23 — — — — 0
’22 — 0 — — 0
’21 1 0 0 0 1
’20 9 — 1 0 10
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 (9) (19) — — —
’25 (11) (16) (18) (27) (72)
’24 (11) (9) (8) (4) (31)
’23 (12) (7) (9) (8) (35)
’22 (14) (16) (9) (8) (46)
’21 (14) (14) (17) (13) (57)
’20 (4) (15) (12) (10) (39)
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 (9) (18) — — —
’25 (11) (17) (18) (27) (72)
’24 (11) (9) (8) (4) (31)
’23 (12) (7) (9) (8) (35)
’22 (14) (16) (9) (8) (47)
’21 (14) (14) (17) (13) (58)
’20 (4) (15) (12) (10) (39)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

1
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Ten-year view Analyst estimates Powerpack
Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 TTM Jun ’26 Trend 10 yrs 2026e 2027e 2028e Next 3/yr
Income, $m
Income, $m Revenue 0 — — — 10 1 0 0 — 11 1 +103.0% 2 5 8 (8.9%)
Gross margin, % 100.00 0.00 0.00 0.00 100.00 100.00 100.00 100.00 — 100.00 19.72 0.0 pt
EBT (32) (33) (48) (58) (51) (63) (47) (37) (18) (152) (163) +19.0%
EBT margin, % (171,944.86) 0.00 0.00 0.00 (502.09) (5,468.82) (62,251.73) (368,994.00) 0.00 (1,401.16) 0.00 +170,543.7 pt
Net income (32) (33) (48) (58) (51) (63) (47) (37) (38) (154) (165) +19.1%
Per share, $
Per share, $ Revenue 0.09 0.00 0.00 0.00 22.23 2.25 0.14 0.02 0.00 1.04 0.00 +31.8%
Earnings (150.00) (113.00) (118.00) (134.00) (112.00) (123.00) (89.00) (58.00) (58.75) (12.81) (6.72) (23.9%)
Cash flow (139.85) (101.25) (105.56) (120.17) (85.83) (111.74) (88.44) (55.07) (48.23) (6.87) (2.38) (28.5%)
Capex (3.31) (1.00) (0.31) (0.33) (0.15) (0.03) (0.16) (0.03) 0.03 (0.09) 0.03 (33.2%)
Free cash flow (143.16) (102.25) (105.86) (120.50) (85.98) (111.77) (88.60) (55.10) (48.20) (6.96) (2.35) (28.5%)
Book value 166.04 407.15 500.52 356.45 280.45 158.61 81.72 60.65 (24.01) 19.49 5.35 (21.2%)
Shares, m 0 0 0 0 0 1 1 1 1 10 22 +54.1%
Valuation, ×
Valuation, × P/E 0.00 — — — 0.00 0.00 0.00 0.00 — 0.00 0.00 0.0
P/S 3.80 — — — 16.88 63.89 852.55 960.87 — 688.83 337.85 431.1
P/B 3.78 — — — 1.34 0.91 3.56 4.48 — 0.62 2.58 2.4
EV/Sales 2.66 — — — 3.61 (13.15) 586.10 729.25 — (291.15) 227.76 169.6
EV/FCF (3.06) — — — (0.94) 0.27 (2.26) (3.75) — 0.72 (3.86) (1.5)
Cash, $m
Cash, $m Operating cash flow (30) (30) (43) (52) (39) (57) (46) (35) (31) (72) (73) +10.2%
Capex (1) 0 0 0 0 0 0 0 0 (1) 1 +3.0%
Free cash flow (30) (30) (43) (52) (39) (58) (47) (35) (31) (72) (72) +10.1%
Balance, $m
Balance, $m Working capital 34 119 204 152 126 79 42 37 25 201 160 +21.7%
Net debt (40) (124) (210) (155) (135) (89) (48) (42) 3 (213) (172) +20.4%
Shareholders’ equity 35 120 205 154 128 82 43 38 (15) 203 163 +21.5%
Returns, %
Returns, % ROA (70.03) (38.93) (28.11) (30.25) (32.84) (53.48) (63.89) (75.98) (93.61) (96.73) (88.26) (26.7) pt
ROIC 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0 pt
ROE (83.96) (42.94) (29.69) (32.19) (36.14) (60.46) (74.98) (90.72) (330.31) (145.42) (101.95) (61.5) pt
People
People Employees 42 40 50 57 54 52 39 35 4 44 — +0.5%
Revenue/emp, $m 0.00 0.00 0.00 0.00 0.19 0.02 0.00 0.00 0.00 0.25 — +102.0%
Negative figures in brackets.
estimates

All 10 years →

Fiscal years to Dec 2025 · latest quarter Mar 2026 · fundamentals updated 26 Oct 2026

Crescent Biopharma, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
OVID Ovid Therapeutics $503.9M — (loss-making) — (loss-making) +463.85% (above 0%: growing) n/m −268.54% (below 0%: shrinking) 100.00% (2,141.61%) Compare
CAPR Capricor Therapeutics, Inc. $500.0M — (loss-making) — (loss-making) −7.92% (below 0%: shrinking) n/m −72.88% (below 0%: shrinking) 100.00% 0.00% Compare
DMAC DiaMedica Therapeutics, Inc. $487.5M — (loss-making) — (loss-making) — n/m −6.75% (below 0%: shrinking) 0.00% 0.00% Compare
RGNX REGENXBIO Inc. $487.2M — (loss-making) — (loss-making) −69.19% (below 0%: shrinking) n/m +168.05% (above 0%: growing) 87.55% (387.84%) Compare
INDP Indaptus Therapeutics, Inc. $485.3M — (loss-making) — — n/m +52.03% (above 0%: growing) 0.00% 0.00% Compare
CBIO Crescent Biopharma, Inc. $480.6M — (loss-making) — (loss-making) +1,038,900.00% (above 0%: growing) n/m −7.04% (below 0%: shrinking) 100.00% 0.00%
MDXG MiMedx Group, Inc $478.6M — (loss-making) — (loss-making) −45.23% (below 0%: shrinking) n/m −87.21% (below 0%: shrinking) 79.80% (18.79%) Compare
CTMX CytomX Therapeutics, Inc. $466.3M — (loss-making) — (loss-making) −71.69% (below 0%: shrinking) n/m +204.14% (above 0%: growing) 100.00% (1,392.30%) Compare
ETRA Electra Therapeutics Inc. $461.3M — — — — — — — Compare
Median of peers $486.3M — — −45.23% — −6.75% 87.55% (18.79%)

All 621 Biotechnology stocks →

Pay and ownership Proxy statement filed 21 April 2026

Chief executive’s pay

Year Total pay Actually paid $100 invested
2025 13.12m 17.58m 3.91
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s shares at the start of the earliest year shown was worth at each year’s end. Read the proxy statement

Crescent Biopharma, Inc. (CBIO) Latest News

15 Oct

Impact 4 · · GlobeNewswire

5 Oct

Impact 4 · · GlobeNewswire

30 Jul

Impact 3 ·

16 Jul

Impact 3 ·

14 Jul

Impact 3 ·

29 Apr

Impact 3 · · GlobeNewswire

26 Feb

Impact 4 · · GlobeNewswire
Impact 3 · · Associated Press Finance

18 Feb

Impact 4 · · GlobeNewswire

5 Feb

Impact 3 · · GlobeNewswireMT NewswiresBioPharma DiveMT NewswiresMT NewswiresInsider MonkeyInsider MonkeyInsider Monkey

30 Jan

Impact 3 · · GlobeNewswire

5 Jan

Impact 4 · · GlobeNewswire
Impact 4 · · PR Newswire
Impact 3 · · PR NewswirePharmaceutical TechnologyPharmaceutical TechnologyBioPharma Dive

18 Dec

Impact 3 · · GlobeNewswire

5 Dec

Impact 4 · · pharmaceutical-technology.com

4 Dec

Impact 4 ·
Impact 4 · · GlobeNewswire
Impact 4 · · GlobeNewswire

17 Nov

Impact 3 ·

6 Nov

Impact 4 · · GlobeNewswire
Impact 3 ·

5 Nov

Impact 3 · · GlobeNewswire

4 Nov

Impact 4 · · GlobeNewswire

17 Sep

Impact 4 · · Simply Wall St.

28 Aug

Impact 3 · · GlobeNewswire

31 Jul

Impact 4 · · GlobeNewswire
Impact 3 ·

8 Jul

Impact 3 ·

5 Jun

Impact 4 ·
stockrow.com/CBIO · Data as of Oct 26, 2026 · For information only; not investment advice. · © 2026 stockrow.com